Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Serum Cortisol Predicts Death and Critical Disease

By LabMedica International staff writers
Posted on 12 Dec 2012
Several biomarkers and prognostic scores have been evaluated to predict prognosis in community-acquired pneumonia (CAP). More...


Serum cortisol concentration is associated with severity and mortality and predicts persistent clinical instability, making it a potential parameter to improve the identification of patients with high risk for a complicated disease course.

Scientists at the University Hospital Carl Gustav Carus (Dresden, Germany) studied 984 hospitalized CAP-patients and measured their serum cortisol concentrations and compared its prognostic accuracy to the leucocyte count, C-reactive protein levels, and the clinical prediction CRB-65 score. Serum cortisol was analyzed by a chemiluminescence immunoassay (Roche Diagnostics; Mannheim, Germany). This assay has a measurement range of 0.5 to 1,750 nmol/L; higher concentrations were analyzed by dilution of the serum sample.

Serum cortisol levels on admission were significantly higher in nonsurvivors at a median of 870 nmol/L when compared to survivors at 602 nmol/L. In patients with critical pneumonia the median was 972 nmol/L compared with a median 598 nmol/L in patients with noncritical pneumonia. In subgroup analyses, cortisol independently predicted critical pneumonia when compared to procalcitonin levels.

A causative microbiological pathogen was detected in 195 patients (20%). Of these, typical bacteria were found in 84 patients (43%), atypical bacteria in 64 (33%), viruses in 29 (15%) and mixed infection in 18 (9%). Streptococcus pneumoniae was the most frequently isolated pathogen and was found in 71 patients (36%).

The authors concluded that cortisol predicts mortality and critical disease in hospitalized CAP-patients independently of clinical scores and inflammatory biomarkers. They recommend that it should be incorporated into trials assessing optimal combinations of clinical criteria and biomarkers to improve initial high-risk prediction in CAP. The study was originally published in April 2012 in the Biomedical Central Journal BMC Infectious Diseases.

Related Links:

University Hospital Carl Gustav Carus
Roche Diagnostics




Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.